18 results about "ScFv Antibodies" patented technology

A conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment that binds to human EpCAM protein, the IgG antibody or antibody fragment comprising a light chain variable region having three complementarity-determining regions L1, L2, and L3, and a heavy chain variable region having three complementarity-determining regions H1, H2, and H3; and at least one scFv antibody fragment that binds to a T lymphocyte protein linked to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.

The object of the present invention is to provide an active ingredient for a systemically administered mRNA pharmaceutical that expresses an antibody specific to the V antigen protein or its homologous protein of Gram-negative bacteria, and a systemically administered mRNA pharmaceutical using the same. [Solution] mRNA containing an antibody coding region encoding a specific scFv antibody against the V antigen protein or its homologous protein of pathogenic Gram-negative bacteria is useful as an active ingredient in mRNA pharmaceuticals for systemic administration.

This invention provides a method for preparing a non-natural humanized chimeric anti-human CD45RA antigen receptor, which specifically binds to the human CD45RA antigen by expressing CAR protein on T cells. Based on a humanized 3A4 antibody, this invention constructs a lentiviral expression vector pLenti / Hu3A4-4-1BB-3ζ. Compared with murine CAR, the humanized CAR significantly reduces immunogenicity, noticeably decreases the production of anti-scFv antibodies, and avoids the HAMA reaction. Research results show that Hu3A4CAR-T cells can specifically bind to the CD45RA-highly expressing myeloid leukemia cell line KG1a. Hu3A4CAR-T cells can target and kill 3A4-positive cell lines and leukemia cells, alleviate the human anti-mouse antibody response, and significantly reduce the production of anti-scFv antibodies, thereby ensuring the CAR's killing activity.

Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.

The invention belongs to the technical field of antibodies, particularly discloses an antibody for treating ulcerative colitis and application of the antibody, and particularly relates to a fully human single-chain antibody (ScFv) specifically combined with human IL-23 and application of the fully human single-chain antibody in treatment of ulcerative colitis. According to the antibody, a fully human bacteriophage ScFv antibody library is constructed, high-affinity IL-23 specific ScFv clone is obtained through three rounds of panning, and the antibody is named as P23A. ELISA detection shows that EC50 of the P23A to IL-23 is 10 nM, and the P23A has high affinity. In a TNBS-induced humanized mouse IBD model, the P23A can significantly improve weight loss of a mouse, reduce the score of a disease activity index (DAI) and recover the length of damaged intestinal tissues, and the treatment effect is equivalent to that of a positive control drug Guselkumab. The antibody provided by the invention has the advantages of high specificity, low immunogenicity and the like, and can be used for preparing medicines for treating ulcerative colitis and other IL-23 related diseases.

The invention belongs to the technical field of biology, and relates to a fully human anti-BCMA monoclonal antibody, a tandem antibody and application thereof. The invention provides an elutriation method of a BCMA protein monoclonal antibody, preparation of an IgG antibody and optimization of a series antibody of the IgG antibody. The scFv monoclonal antibody is composed of a light chain variable region VL, a heavy chain variable region VH and a human Fc fragment. The base sequence of the scFv monoclonal antibody is as shown in SEQ ID No.9, and the amino acid sequence of the scFv monoclonal antibody is as shown in SEQ ID No.23. The anti-human BCMA IgG antibody can specifically recognize and bind to human BCMA protein, and the binding activity of the anti-human BCMA IgG antibody is remarkably improved after the anti-human BCMA IgG antibody is expressed in a series scFv antibody form. The tandem antibody has a wide application prospect in detection of human BCMA protein and treatment of related target diseases, and a new idea is provided for development of antibody diagnostic reagents and drugs.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

The invention discloses an anti-CDH11 scFv antibody and application thereof, and relates to the technical field of monoclonal antibody screening synthesis, the anti-CDH11 scFv antibody comprises a first group: SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, RNN and SEQ ID NO.5; or, a second group: SEQ ID NO.6, SEQ ID NO.7, SEQ ID NO.8, SEQ ID NO.9, GKN, and SEQ ID NO.10; or a third group: SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, RNN and SEQ ID NO. 15. The scfv antibody, the full-length IgG antibody and the monoclonal antibody can specifically recognize CDH11 protein, and can be widely applied to flow detection or kit detection of CDH11 surface expression cells.

The present invention addresses the problem of providing: lipid nanoparticles that enable selective delivery of a nucleic acid to a target cell; or a method for measuring the optimal density for selective delivery of a nucleic acid to a target cell. Provided are lipid nanoparticles that include: a nucleic acid encapsulated in the lipid nanoparticles; a cationic lipid; a sterol or a sterol derivative; an antibody selected from a VHH antibody, an Fab antibody, and an scFv antibody; a targeting polyalkylene glycol-modified lipid; and a non-targeting polyalkylene glycol-modified lipid. The antibody targets an antigen on a T-cell. The targeting polyalkylene glycol-modified lipid is a lipid in which the antibody is linked to polyalkylene glycol. The non-targeting polyalkylene glycol-modified lipid is a lipid not linked to the antibody. The density of the VHH antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.004-2.300 per 100 nm2 of the nanoparticle surfaces. The density of the Fab antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces. The density of the scFv antibody existing on the surfaces of the lipid nanoparticles in a state capable of binding to the antigen is 0.003-1.113 per 100 nm2 of the nanoparticle surfaces.

The present application relates to the technical field of immune detection, in particular to a single-chain antibody for detecting Helicobacter pylori and application thereof. The present application constructs an avian scFv antibody library for Helicobacter pylori whole-bacterium lytic protein by using phage display technology, and screens a single-chain antibody for detecting Helicobacter pylori from the scFv antibody library, which comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO: 1-3 respectively, and the light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO: 4-6 respectively. The single-chain antibody has the characteristics of high detection accuracy and strong specificity, and has the potential for treating Helicobacter pylori. In addition, the present application can be expressed on a large scale and is suitable for industrial production.

The invention belongs to the technical field of biological medicines, and discloses an scFV fragment and application thereof in preparation of a medicine for treating neuroblastoma. The invention discloses an scFV (single chain factor virus) antibody for resisting ERBB4 (endothelial cell binding protein 4). By designing an scFV fragment specifically combined with an ERBB4 extracellular domain and meanwhile designing ERBB4. CAR T, experimental verification shows that compared with traditional CD3 + T cells, CART designed by targeting ERBB4 extracellular domain scFV can effectively activate T cells after co-culture with NB cells and has a stronger tumor killing effect, the feasibility of the ERBB4. CAR T for preventing NB development and recurrence is prompted, and the CART has a good application prospect. The fusion protein has a good clinical transformation value, and has an important significance in treatment of neuroblastoma.

The present invention provides a multispecific antibody having at least one conditional activity and a method for producing the same. [Solution] A multispecific antibody comprises at least one binding site for a cell-specific antigen and at least one binding site for a tumor-reactive lymphocyte antigen, and the multispecific antibody comprises an IgG antibody or fragment thereof that binds to a first antigen; and at least one scFv antibody that binds to a second antigen different from the first antigen and is ligated to the C-terminus of at least one light chain or heavy chain of the IgG antibody or fragment. This multispecific antibody reversibly binds to the cell-specific antigen and the tumor-reactive lymphocyte antigen or at least one of the first antigen and the second antigen with greater affinity under abnormal conditions than under normal physiological conditions. Conjugates of multispecific antibodies and methods for producing multispecific antibodies are also provided.

Provided are an anti-PSMA single-chain antibody, a chimeric antigen receptor associated therewith and use thereof. An amino acid sequence of a heavy chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 1, and an amino acid sequence of a light chain of the anti-PSMA single-chain antibody includes a sequence shown in SEQ ID NO: 2. The anti-PSMA single-chain antibody is a humanized scFv antibody of PSMA, is more functional in the human body, has better compatibility, and is less prone to be rejected by the immune system. The chimeric antigen receptor has better response effects after specifically bonding to PSMA so that CAR-T cells generate a stronger immune response to tumors, and the chimeric antigen receptor also has better long-term effectiveness than other PSMA chimeric antigen receptors.

A monoclonal antibody used for specifically binding to CAR molecules, which is characterized in that the monoclonal antibody comprises a light chain and a heavy chain, the light chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 1-3, and the heavy chain comprises CDR regions having an amino acid sequence as shown in SEQ ID NO: 5-7. By using the described monoclonal antibody or a CAR-T cell detection kit, the steps of CAR-T cell detection are simple, detection time is short, and the detection results are stable. An anti-FMC63 ScFv antibody can reduce the cost of detecting universal anti-CD19 CAR-T cells.

The application belongs to the technical field of antibodies, and specifically discloses an antibody for treating ulcerative colitis and application thereof, and particularly relates to a full human single-chain antibody (ScFv) specifically combined with human IL-23 and application of the full human single-chain antibody (ScFv) in treating ulcerative colitis. The antibody is obtained by constructing a full human phage ScFv antibody library, and a high-affinity IL-23 specific ScFv clone is obtained through three rounds of panning and is named P23A. ELISA detection shows that the EC50 of P23A to IL-23 is 10 nM, and P23A has high affinity. In a TNBS-induced humanized mouse IBD model, P23A can significantly improve the weight loss of mice, reduce the disease activity index (DAI) score, and restore the length of damaged intestinal tissue, and the treatment effect is equivalent to that of a positive control drug Guselkumab. The antibody provided by the application has the advantages of high specificity and low immunogenicity, and can be used for preparing a drug for treating ulcerative colitis and other IL-23 related diseases.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CD112, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

Chimeric antigen receptors (CARs) that are expressible by cells of the immune system such as T cells or NK cells (CAR-T and CAR-NK). These CARs comprise a fragment of scFv antibody directed against a specific antigen of tumor tissues, the tumor activated Trop-2 antigen wherein said activated Trop-2 is the Trop-2 molecule proteolytically cleaved between R87 and T88. The invention also involves the use of CAR constructs for use in anti-tumor cell therapy.

The present invention provides a conditionally active bispecific antibody comprising: an IgG antibody or antibody fragment binding to a human EpCAM protein, comprising a light chain variable region having three complementarity determining regions L1, L2 and L3 and a heavy chain variable region having three complementarity determining regions H1, H2 and H3; and at least one scFv antibody fragment binding to a T-lymphocyte protein attached to the C-terminus of at least one light chain of the IgG antibody or antibody fragment.